{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:57:54Z","timestamp":1773680274015,"version":"3.50.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.01163","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T04:55:56Z","timestamp":1596776156000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma"],"prefix":"10.3389","volume":"10","author":[{"given":"Claudia C. V.","family":"Lang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egle","family":"Ramelyte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/ddg.13164","article-title":"Cutaneous B-cell lymphomas - pathogenesis, diagnostic workup, and therapy","volume":"14","author":"Nicolay","year":"2016","journal-title":"J Dtsch Dermatol Ges."},{"key":"B3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British association of dermatologists and UK Cutaneous Lymphoma group guidelines for the management of primary cutaneous lymphomas","volume":"180","author":"Gilson","year":"2019","journal-title":"Br J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jamadermatol.2013.7452","article-title":"Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France","volume":"150","author":"Grange","year":"2014","journal-title":"JAMA Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","article-title":"European organization for research and treatment of cancer and international society for cutaneous lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas","volume":"112","author":"Senff","year":"2008","journal-title":"Blood."},{"key":"B7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the international lymphoma radiation oncology group","volume":"92","author":"Specht","year":"2015","journal-title":"Int J Rad Oncol Biol Phys."},{"key":"B8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ijrobp.2008.06.1918","article-title":"Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas","volume":"74","author":"Neelis","year":"2009","journal-title":"Int J Rad Oncol Biol Phys."},{"key":"B9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1365-2133.2010.09798.x","article-title":"Intralesional corticosteroid therapy for primary cutaneous B-cell lymphoma","volume":"163","author":"Perry","year":"2010","journal-title":"Br J Dermatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1080\/10428190500399698","article-title":"Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma","volume":"47","author":"Cozzio","year":"2006","journal-title":"Leuk Lymphoma."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e83670","DOI":"10.1371\/journal.pone.0083670","article-title":"TG1042 (Adenovirus-interferon-gamma) in primary cutaneous B-cell lymphomas: a phase II clinical trial","volume":"9","author":"Dreno","year":"2014","journal-title":"PLoS ONE."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: a new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1473-3099(01)00095-0","article-title":"Topical immunomodulators\u2013progress towards treating inflammation, infection, and cancer","volume":"1","author":"Hengge","year":"2001","journal-title":"Lancet Infect Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000241302","article-title":"New and experimental skin-directed therapies for cutaneous lymphomas","volume":"22","author":"Farkas","year":"2009","journal-title":"Skin Pharmacol Physiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/jdv.12026","article-title":"European guidelines for topical photodynamic therapy part 2: emerging indications\u2013field cancerization, photorejuvenation and inflammatory\/infective dermatoses","volume":"27","author":"Morton","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jaad.2005.10.016","article-title":"Topical photodynamic therapy for primary cutaneous B-cell lymphoma: a pilot study","volume":"54","author":"Mori","year":"2006","journal-title":"J Am Acad Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/bjd.12484","article-title":"Long-term outcome of intravenous therapy with rituximab in patients with primary cutaneous B-cell lymphomas","volume":"169","author":"Brandenburg","year":"2013","journal-title":"Br J Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/1097-0142(20001015)89:8<","article-title":"Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma","volume":"89","author":"Heinzerling","year":"2000","journal-title":"Cancer."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1111\/bjh.16211","article-title":"Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"187","author":"Di Raimondo","year":"2019","journal-title":"Br J Haematol."},{"key":"B22","unstructured":""},{"key":"B23","unstructured":""},{"key":"B24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/978-0-387-89520-8_2","article-title":"Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges","volume":"647","author":"Law","year":"2009","journal-title":"Adv Exp Med Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.cgt.7700527","article-title":"Prospects for CD40-directed experimental therapy of human cancer","volume":"10","author":"Tong","year":"2003","journal-title":"Cancer Gene Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"8331","DOI":"10.1158\/0008-5472.CAN-05-0095","article-title":"Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40","volume":"65","author":"Law","year":"2005","journal-title":"Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1756-8722-7-44","article-title":"A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors","volume":"7","author":"de Vos","year":"2014","journal-title":"J Hematol Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.2217\/fon-2018-0325","article-title":"Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia","volume":"14","author":"Gbadamosi","year":"2018","journal-title":"Future Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.yexcr.2011.03.010","article-title":"Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab","volume":"317","author":"Nagorsen","year":"2011","journal-title":"Exp Cell Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: a historical perspective","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/16078454.2018.1549802","article-title":"Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed\/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis","volume":"24","author":"Yu","year":"2019","journal-title":"Hematology."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood."},{"key":"B34","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA approval summary: nivolumab for the treatment of relapsed or progressive classical hodgkin lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.jid.2018.04.038","article-title":"Genomic analyses identify recurrent alterations in immune evasion genes in diffuse large B-cell lymphoma, leg type","volume":"138","author":"Zhou","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and sezary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","article-title":"Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis","volume":"37","author":"Cinar","year":"2013","journal-title":"Leuk Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood."},{"key":"B39","doi-asserted-by":"publisher","first-page":"624","DOI":"10.2174\/187152007784111331","article-title":"Bruton's tyrosine kinase as a new therapeutic target","volume":"7","author":"Uckun","year":"2007","journal-title":"Anticancer Agents Med Chem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell."},{"key":"B41","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1158\/0008-5472.CAN-14-2362","article-title":"Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma","volume":"75","author":"Yang","year":"2015","journal-title":"Cancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1182\/blood-2017-05-786988","article-title":"A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib","volume":"130","author":"Winter","year":"2017","journal-title":"Blood."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.3390\/ijms19061758","article-title":"Molecular mechanisms of disease progression in primary cutaneous diffuse large B-cell lymphoma, leg type during ibrutinib therapy","volume":"19","author":"Fox","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1111\/bph.14809","article-title":"A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk(C481S) mutation in B-cell malignancies","volume":"176","author":"Gui","year":"2019","journal-title":"Br J Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2007.14.5367","article-title":"Lenalidomide for the treatment of B-cell malignancies","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.jid.2018.03.1516","article-title":"A single-arm phase II trial of lenalidomide in relapsing or refractory primary cutaneous large B-cell lymphoma, leg type","volume":"138","author":"Beylot-Barry","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B50","first-page":"3","article-title":"Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma","volume":"2","author":"Tsujimoto","year":"1987","journal-title":"Oncogene."},{"key":"B51","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1172\/JCI28281","article-title":"Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737","volume":"117","author":"Del Gaizo Moore","year":"2007","journal-title":"J Clin Invest."},{"key":"B52","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11523-018-0560-7","article-title":"Targeting BCL-2 in Hematologic Malignancies","volume":"13","author":"Khan","year":"2018","journal-title":"Target Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01163\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T04:55:58Z","timestamp":1596776158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01163\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,7]]},"references-count":53,"alternative-id":["10.3389\/fonc.2020.01163"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.01163","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,7]]},"article-number":"1163"}}